Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Other financing activities (2018 - 2022)

Editas Medicine (EDIT) reported Other financing activities of $367000.0 for Q2 2022, down 30.23% year-over-year from $526000.0 in Q2 2021, and down 30.23% on a QoQ basis from $526000.0 in Q2 2021.

Editas Medicine (EDIT) has 5 years of Other financing activities data on file, last reported at $367000.0 in Q2 2022.

  • Quarterly Other financing activities fell 30.23% year-over-year to $367000.0 in Q2 2022, while the trailing twelve-month figure through Jun 2022 was $1.5 million (changed 0.33% YoY) and the FY2022 annual result came in at $979000.0, down 15.02% from the prior year.
  • Other financing activities declined to $367000.0 in Q2 2022 per EDIT's latest filing, from $526000.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $526000.0 in Q2 2021 and bottomed at $100000.0 in Q1 2018.
  • The 5-year median for Other financing activities is $356000.0 (2018), against an average of $331333.3.
  • The widest annual swing landed in 2021, when Other financing activities surged 50.29%; it then slumped 30.23% in 2022.
  • Tracing EDIT's Other financing activities over 5 years: stood at $362000.0 in 2018, then declined by 21.82% to $283000.0 in 2019, then rose by 23.67% to $350000.0 in 2020, then surged by 50.29% to $526000.0 in 2021, then tumbled by 30.23% to $367000.0 in 2022.
  • Per Business Quant, the three latest EDIT Other financing activities figures stand at $367000.0 (Q2 2022), $526000.0 (Q2 2021), and $350000.0 (Q2 2020).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn -
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn -
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn
7 Evaxion A 64.16 Bn 64.14 Bn -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn
10 Editas Medicine 338.62 Mn 338.62 Mn -

Historic Data

Download Data 🔒
DateValue
Jun 30, 2022 367,000.00
Jun 30, 2022 367,000.00
Jun 30, 2021 526,000.00
Jun 30, 2021 526,000.00
Jun 30, 2020 350,000.00
Jun 30, 2020 350,000.00
Jun 30, 2019 283,000.00
Jun 30, 2019 283,000.00
Jun 30, 2018 362,000.00
Jun 30, 2018 362,000.00
Mar 31, 2018 100,000.00
Mar 31, 2018 100,000.00